Evidence map›Paper›PMID 39329526›Full record

ArticlemBio2024

The feasibility of establishing a hamster model for HBV infection:

Hu Zhang, Yanan Liu, Cheng-Der Liu, Zhongde Wang, Haitao Guo

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hu Zhang *Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Yanan Liu *Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.
Cheng-Der LiuCancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Zhongde WangDepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.ORCID 0000-0003-2441-4729
Haitao GuoCancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-7146-916X

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5M
The Role of HBeAg in HBV PersistenceR01AI134818 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Haitao Guo · 2018 to 2026
$2.7M
Development of a hamster model for hepatitis B virus infectionR01AI183883 · NIAID · UTAH STATE UNIVERSITY · PI Haitao Guo, Zhongde Wang · 2024 to 2026
$2.2M
Epigenetic Regulation of HBV cccDNA TranscriptionR01AI150255 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2020 to 2024
$2.0M
Human Liver Tissue & Hepatocytes Research Resource (HLTHRR)R24DK139775 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVID A GELLER, Satdarshan Singh Monga · 2024 to 2026
$1.4M
High throughput screening and preclinical development of HBV cccDNA inhibitorsR21AI179929 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2024 to 2025
$426k
HHS | NIH | National Cancer Institute (NCI) P30CA047904HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI110762, R01AI150255HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI183883NCI NIH HHS P30 CA047904NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI134818NIAID NIH HHS R01 AI150255NIAID NIH HHS R01 AI183883NIAID NIH HHS R21 AI179929NIDDK NIH HHS P30 DK120531NIDDK NIH HHS R24 DK139775
6 · The paper itself

Abstract

Chronic hepatitis B virus (HBV) infection remains a significant public health burden with no cure currently available. The research to cure HBV has long been hampered by the lack of immunocompetent small animal models capable of supporting HBV infection. Here, we set out to explore the feasibility of the golden Syrian hamster as an immunocompetent small rodent model for HBV infection. We first started with

Indexed as

Disease Models, AnimalHepatitis B virusHepatocytesVirus ReplicationAdenoviridaeAnimalsCells, CulturedCricetinaeHepatitis BHumansMesocricetusOrganic Anion Transporters, Sodium-DependentSymportersOrganic Anion Transporters, Sodium-Dependentsodium-bile acid cotransporterSymporterscccDNAhamster hepatocyteshepatitis B virusNTCP

Identifiers

PMID39329526
PMCPMC11559161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.